Eli Lilly (LLY) Announces Positive Phase 3 Results for Jaypirca Combination in R

Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 clinical trial, which evaluated the addition of Jaypirca (pirtobrutinib) to a time-limited venetoclax and rituximab regimen for patients with relapsed or refractory chronic lymphocytic leukemia/CLL or small lymphocytic lymphoma/SLL. The study met its primary endpoint, showing that the pirtobrutinib combination reduced the risk of disease progression or death by 45% compared to the control arm of venetoclax and rituximab alone.

The trial enrolled 639 patients, nearly 80% of whom had been previously treated with a covalent BTK inhibitor, making the findings highly relevant to current clinical practices. At a median follow-up of 27.3 months, the median progression-free survival/PFS in the pirtobrutinib arm had not been reached, compared to 39.7 months in the control arm. These benefits were consistent across various high-risk patient subgroups, and the pirtobrutinib combination also showed a significant advantage in the time to next treatment.

The safety profile of the regimen was consistent with the known profiles of the

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/eli-lilly-lly-announces-positive-112148243.html)